Biotechnology Entrepreneur Joins OneWorld Health Board of Directors

Share Article

Nigel Ten Fleming, Ph.D., Co-Founder, Chairman and CEO of G2B Pharma Joins Board of Bay Area Global Health Non-Profit Organization

We are poised to make substantial contributions to global health in the near and long term.

The Institute for OneWorld Health, a leading global health research and development organization that develops drugs for people with neglected infectious diseases in the developing world, today announced the appointment of Nigel Ten Fleming, Ph.D., to its Board of Directors.

Dr. Fleming is a biotechnology entrepreneur who brings a wide range of experience in the healthcare, biotechnology, and pharmaceutical industries to OneWorld Health. He is the co-founder of G2B Pharma, a privately-held developmental stage specialty pharmaceutical company focused on the reformulation of off-patent drugs, where he currently serves as Chairman and CEO. Previously, Dr. Fleming founded Minerva Healthcare, a specialty pharmaceutical company focused on drugs for metabolic syndrome, where he served as Chairman and CEO. He has consulted and served in leadership roles for numerous biotechnology companies during the past twenty years.

"We are excited to welcome to our board an individual with such a diverse background and successful track record," said Dr. Richard Chin, M.D., OneWorld Health's Chief Executive Officer. "Nigel's experience in guiding biotechnology companies through different stages of growth will be a great asset as we advance our mission to develop medicines for those who need them the most but can afford them the least."

"I am pleased to be joining OneWorld Health at such a pivotal time in the organization's development," said Dr. Fleming. "We are poised to make substantial contributions to global health in the near and long term."

Born and brought up in Kenya, Dr. Fleming completed his early education in England. He received his undergraduate degree as a Morehead Scholar from the University of North Carolina at Chapel Hill with highest honors, completed a Ph.D. in Clinical Biochemistry at Cambridge University, was a post-doctoral researcher at the Boston University School of Medicine, and has served both as a tutor at Harvard University and a lecturer at Harvard Medical School, while doing research at Harvard.

Dr. Fleming also founded Athena Diagnostics, a neurological diagnostics reference laboratory, serving as Chairman, CEO and Vice President of Business Development prior to the company's sale to Athena Neuroscienses/Elan Pharmaceuticals in 1995. He joined Athena/Elan, and Athena Diagnostics was later sold for $283 M to Fisher Scientific. He has also served on the boards of directors at Exemplar, a subsidiary of Transgenic Sciences Inc (NasdaqTSI), Impax Labs (Nasdaq: IPXL), and Genmedica Therapeutics, and served senior roles in Gamera Biosciences, Neurocal, Nephros, TheraMed Partners and Plant Cell Technologies.

About the Institute for OneWorld Health
The Institute for OneWorld Health, the first US nonprofit pharmaceutical company, develops safe, effective and affordable medicines for people with neglected diseases of the developing world. The Institute for OneWorld Health, headquartered in San Francisco, California, USA, is a tax-exempt 501 (c) (3) US corporation. (http://www.oneworldhealth.org/). Media resources are available at http://www.oneworldhealth.org/media/index.php/.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website